Quick Facts

• Therapeutic Domains: Symptom management for certain types of pain and dysmenorrhea.
• Targeted Conditions: Temporary relief of mild to moderate pain; management of menstrual pain.

---

What Adco-Mefenamic Acid Treats: Main Uses and Benefits

Adco-Mefenamic Acid is a medication used in the symptom management of specific temporary conditions. It serves a therapeutic role in providing relief from mild to moderate acute pain. This may include pain arising from dental procedures or musculoskeletal sources.

The medication is also utilized to address discomfort associated with primary dysmenorrhea (menstrual pain). This indicates its use is generally intended for short-term application, aligned with the duration of the pain or menstrual period.

The clinical use of this treatment is intended to assist in managing the physical signs of these conditions. It is important that patients use this medication as recommended by a healthcare professional and for no longer than the prescribed duration. The clinical profile of this medication is centered on its approved indications for pain and inflammatory symptom management.

Eligibility Scope

The official eligibility profile for Mefenamic Acid defines specific populations for whom use is permitted, restricted, or strictly prohibited. Regulatory documents establish that the medicine is approved for use in adults and adolescents 14 years of age and older.

Eligibility Status	Patient/Condition Defined by Regulators
Contraindicated	Known hypersensitivity to any NSAID, active GI ulceration, severe heart failure, severe renal impairment, or post-CABG surgery pain.
Contraindicated	Use during the third trimester of pregnancy (at or after 30 weeks gestation).
Not Recommended	Children under 12 to 14 years of age, as safety and efficacy have not been established for the oral capsule/tablet formulation.
Not Recommended	Women attempting to conceive or who are breastfeeding.
Conditional Use	Patients with pre-existing cardiovascular risk factors (e.g., controlled hypertension, established Ischaemic Heart Disease) require careful consideration.
Conditional Use	Elderly patients (65 years) should use the medicine with caution, often necessitating close renal function monitoring due to increased risk of complications.

Eligibility Classifications

Official labeling classifies these restrictions primarily under Contraindicated, Not Recommended, and Conditional Use (Use with Caution), based on assessments of organ system function (GI, renal, cardiac), developmental stage, and immune status. This classification system strictly limits the eligible population to those who do not possess these documented risk factors.

Interactions with other medicines and products

Adco-Mefenamic Acid, an NSAID, can interact with various medications, necessitating cautious co-administration and monitoring. Concomitant use with other NSAIDs, including COX-2 selective inhibitors, is generally advised against due to an increased risk of serious gastrointestinal side effects suching as bleeding or ulceration.

Increased Bleeding Risk

The risk of bleeding is significantly elevated when mefenamic acid is combined with anticoagulants (like Warfarin), anti-platelet agents (including low-dose Aspirin), corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs). Mefenamic acid can displace Warfarin from protein binding sites, potentially enhancing its effect. Concurrent use with oral anticoagulants requires frequent monitoring of prothrombin time.

Other Significant Interactions

• Antihypertensives: Mefenamic acid may reduce the blood pressure-lowering effect of medications like ACE inhibitors, Angiotensin II Antagonists (AIIA), Diuretics, and Beta-blockers. This antagonism may lead to an increased risk of kidney function deterioration, particularly in elderly or volume-depleted patients.
• Lithium: The combination may lead to a reduction in renal lithium clearance, causing increased plasma lithium levels and a risk of toxicity.
• Methotrexate: Mefenamic acid can reduce the elimination of Methotrexate, potentially increasing its plasma concentration and toxicity.
• Digoxin: Co-administration may increase serum Digoxin levels to potentially harmful concentrations.
• Antacids: Magnesium hydroxide-containing antacids can increase the absorption of mefenamic acid, which may raise the risk of side effects.

Enzyme and Pathway Modulation

Adco-Mefenamic Acid functions as a non-steroidal anti-inflammatory drug (NSAID) by engaging multiple signaling pathways to modulate physiological responses. The primary mechanism involves enzyme-mediated signaling inhibition. The agent acts as a non-selective inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This interaction modifies early molecular steps, resulting in the suppression of prostaglandin biosynthesis, which are key eicosanoid pathway intermediates.

Beyond COX inhibition, the molecule also engages mechanisms that regulate overactive or dysregulated processes in the neuro-sensory system. Research suggests it can modulate specific ion channels, such as the GABA-A receptors, which enhances inhibitory effects and alters neural signal transmission. This dual action, leading to reduced inflammatory mediator concentration and altered neural signaling, induces a shift in the steady-state activity of targeted pathways, resulting in defined alterations in systemic physiological parameters.

How to Use Adco-Mefenamic Acid

Adco-Mefenamic Acid is strictly a prescription-only medication intended for oral administration as a solid dosage form (capsule or tablet). The regimen for use is highly specific and governed by the principle of using the lowest effective dose for the shortest possible duration to manage acute symptoms.

Official Route and Dosing Regimen

The only approved route for this medicine is oral. The primary dosing schedule is standardized across the approved uses, with specific limits on duration.

Condition	Initial Dose	Maintenance Dose & Frequency	Maximum Duration
Acute Pain	500 mg (Loading Dose)	250 mg every 6 hours	Generally not to exceed 7 days
Primary Dysmenorrhea	500 mg (Loading Dose at onset)	250 mg every 6 hours	Limited to 2–3 days of menstruation

This dosing schedule is typically intended for patients 14 years of age and older.

Administration Conditions

To ensure proper use, the medication should be taken with food or milk to facilitate administration. The tablets or capsules must be swallowed whole with water; they should not be crushed, chewed, or opened. If a dose is missed, patients are instructed to take the next dose at the regularly scheduled time and not to double up to compensate. The strict duration limits—such as the 7-day maximum for acute pain—establish that this is a short-term, acute-use treatment only.

Research Evidence / Overview of Studies for Adco-Mefenamic Acid

---

Evidence for Use in Primary Dysmenorrhea (Menstrual Pain)

The research available in the context of outcomes related to physical discomfort during menstruation, a condition characterized by episodic manifestations, is drawn from a large number of Randomized Controlled Trials (RCTs). The data from these individual studies was evaluated in larger Meta-analyses that consolidate findings from many trials to gain a broader perspective. Studies observed adult women and adolescents. Findings from the collective evidence is considered to be high-level, with studies contributing to the broader evidence landscape for this class of medicine. While the research provides significant insight, some Network Meta-analyses comparing Mefenamic Acid to other medications was observed in some studies to have limited comparative evidence on certain specific measures of measured outcomes.

Evidence for Use in Mild to Moderate Acute Pain

The research exploring mild to moderate acute pain—a condition involving periods of heightened symptoms—comes from short-term RCTs and Systematic Reviews. These studies research examined how symptoms change over time in patients with pain arising from specific circumstances, such as pain following dental work or minor surgical procedures. The research was studied for outcomes related to physical discomfort using specific measurements like Summed total pain relief (TOTPAR). These findings findings describe patterns observed in the studies over very short, defined time periods, such as those measured over four to six hours after a single dose. The evidence for acute pain is classified as moderate.

What Remains Uncertain About Mefenamic Acid Research

Clinical studies primarily focus on short-term or episodic symptom patterns. The scientific literature highlights several areas where the evidence is limited or certainty remains low. Because the follow-up durations were limited in most trials, long-term effects are not fully established. Furthermore, comparative evidence is lacking for direct, head-to-head assessments against many different types of common pain relievers. The findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain.

Common questions about Adco-Mefenamic Acid (FAQ)

---

Q: How does Adco-Mefenamic Acid differ from common over-the-counter pain medicines like ibuprofen?

A: Official product information states that Mefenamic Acid belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, similar to ibuprofen. However, chemically, Mefenamic Acid is further defined as an anthranilic acid derivative.

This subclass distinction dictates its unique chemical structure and pharmacological action compared to other common NSAIDs.

---

Q: What are the most commonly reported side effects of Adco-Mefenamic Acid?

A: According to regulatory documents, the most frequently reported adverse reactions relate to the gastrointestinal system.

These commonly observed effects often include symptoms such as abdominal discomfort, nausea, or diarrhea.

---

Q: Are there any long-term safety concerns associated with Adco-Mefenamic Acid use?

A: Official safety information indicates that the risk of serious side effects, particularly involving the cardiovascular and gastrointestinal systems, increases with the duration of use.

For this reason, regulatory guidance specifies that the medicine is intended only for short-term, acute use.

---

Q: Is Adco-Mefenamic Acid considered a narcotic or opioid pain reliever?

A: This medicine is not classified as a narcotic or an opioid pain reliever.

It is defined in regulatory documents as a Non-Steroidal Anti-Inflammatory Drug (NSAID), which acts through different physiological pathways than opioid medicines.

---

Q: What are the signs of an allergic reaction to Adco-Mefenamic Acid?

A: Official documentation lists hypersensitivity reactions as a possible adverse effect.

Signs of an allergic reaction may include skin rash, itching, or swelling of the face or throat, as well as difficulty breathing.

---

Q: Does the medicine come in different strengths, and what do they treat?

A: The medicine is commonly available in multiple dosage strengths, most often as 250 mg capsules/tablets and 500 mg tablets.

These strengths correspond to the amounts used for initial treatment and those used for subsequent maintenance, as defined in the approved schedules.

---

Q: Is it normal to experience dizziness or drowsiness when using this medicine?

A: Yes, official safety information documents effects on the central nervous system (CNS).

Side effects such as dizziness have been reported, and less commonly, patients may experience drowsiness when using the medicine.

---

Q: How quickly should Adco-Mefenamic Acid start providing relief after taking it?

A: Clinical data shows the active ingredient typically reaches its highest level in the blood within approximately two to four hours after administration.

This period generally aligns with the time of maximum concentration of the drug in the body.

---

Q: How long does the effect of one amount of Adco-Mefenamic Acid typically last?

A: The approved dosing schedules are based on pharmacokinetic studies that determine how long the medicine stays active in the body.

Because of this, the approved dosing interval is typically every six hours to sustain the expected therapeutic exposure.

---

Q: Is it safe to consume alcohol while taking Adco-Mefenamic Acid?

A: Official regulatory documents often include cautions regarding the combined use of NSAIDs and alcohol.

The combination may lead to a potentially increased risk of serious gastrointestinal adverse effects, such as stomach bleeding or irritation.

---

Q: Can people with a history of asthma use Adco-Mefenamic Acid?

A: Official product information specifies that this medicine is contraindicated (meaning use is prohibited) if a person has experienced asthma, hives (urticaria), or allergic-type reactions after taking aspirin or any other NSAID medicine.

---

Q: Is it possible to become dependent on Adco-Mefenamic Acid?

A: No. According to regulatory documents, Mefenamic Acid has been assessed and its labeling states there is no evidence of dependence or abuse potential associated with its use.

---

Q: Why does the packaging warn about driving or operating machinery?

A: The packaging includes a warning about operating machinery due to potential central nervous system side effects documented in clinical use.

Since effects like dizziness or blurred vision have been reported, the warning is a safety measure against impaired alertness.

---

Q: Can this medicine affect people with high blood pressure?

A: Yes, official warnings state that NSAIDs may cause a new onset or a worsening of pre-existing hypertension (high blood pressure).

Furthermore, the medicine may reduce the blood pressure-lowering effect of certain antihypertensive medications.

---

Q: What is the risk of overdose with Adco-Mefenamic Acid?

A: Information regarding overdosage is documented in regulatory labeling. While initial symptoms may include lethargy, drowsiness, or vomiting, serious outcomes are possible.

These serious outcomes include acute renal failure (kidney failure), coma, or seizures.

How to Store and Dispose of Adco-Mefenamic Acid

Adco-Mefenamic Acid must be stored under specific conditions to maintain its stability and effectiveness. The medicine should be stored at controlled room temperature, which is typically below 25 °C or within the range of 15 °C to 30 °C.

Key Storage Requirements:

• Keep the medicine in its original packaging and store it out of sight and out of reach of children.
• Protect the product from moisture and light.
• Do not use the medicine after the expiration date printed on the container.

Disposal Instructions:

• Unused or expired Adco-Mefenamic Acid should not be disposed of in household waste, drains, or sewerage systems (such as flushing down a toilet).
• For safe and proper disposal, return all unused or unwanted medicine to your pharmacist or healthcare professional.